Global Information
회사소개 | 문의 | 비교리스트

면역치료제, 기기, 환자 참여 유도

Immunotherapeutic Drugs, Devices & Patient Enablement

리서치사 Greystone Research Associates
발행일 2018년 10월 상품 코드 729889
페이지 정보 영문
US $ 3,850 ₩ 4,738,000 PDF by E-mail (Single User License)
US $ 5,500 ₩ 6,769,000 PDF by E-mail (Site License)
US $ 7,500 ₩ 9,231,000 PDF by E-mail (Global License)

면역치료제, 기기, 환자 참여 유도 Immunotherapeutic Drugs, Devices & Patient Enablement
발행일 : 2018년 10월 페이지 정보 : 영문

자가투여용 면역치료제(Immunotherapeutic Drugs) 시장에 대해 조사했으며, 환자 참여 유도 및 자가투여 동향에서의 주요인, 자가투여에 사용되는 인가 면역치료제, 공급 포장, 현재의 자가투여용 면역치료제 시장 규모, 시장 점유율 리더 기업과 시장 점유율 예측, 면역치료제 시장에 영향을 미치는 경제·기술·규제 요인 등의 정보를 정리하여 전해드립니다.

1. 주요 요약

2. 시장 역학

  • 경쟁 구도
  • 투여량당 비용과 관리의료
  • 바이오시밀러
  • 제품 설계와 구현요소
  • 인간공학/인간공학
  • 디바이스 개발 및 공급 포장

3. 자가투여 기기

  • 기기 선정
  • 프리필드 시린지
  • 자동주사기
  • 펜형 주사기
  • 새로운 기기

4. 자가투여 면역치료제 평가

5. 치료 시장 부문 분석과 예측

6. 시장 예측

  • 규제 요인
  • 임상시험 프로토콜 & 엔드포인트
  • 얼라이언스 및 제휴

7. 기업 개요

LSH 18.11.01

Drug Formulation & Packaging Migration Creating Self-Dosing Opportunities

The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward patient enablement and self-administration.

Immunotherapeutic Drugs, Devices & Patient Enablement - What You Will Learn:

  • What approved immunotherapeutic drugs are indicated for self-administration, what is the as-supplied packaging, what are the device specifics, and who markets them?
  • What are the major factors driving the migration of infusible immunotherapeutic drugs to formulations that can be packaged and administered subcutaneously?
  • What is the size of the market for self-administered immunotherapeutic drugs today, who are the market share leaders, and what will the market share be in 2022?
  • How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
  • What are the essential design factors, technologies and market development issues for devices that can deliver injectable immunotherapeutics subcutaneously?
  • What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?

Table of Contents

Executive Summary

Market Dynamics

  • Competitive Landscape
    • Biological Supply Chain Activity
    • FDA/EMA Immunotherapeutics Regulatory Overview
  • Cost per Dose and Managed Care
  • Biosimilars
  • Product Design and Enablement Factors
    • Ease of Use
    • Patient Adherence
  • Human Engineering/Ergonomics
    • Patient-centered Design
    • Patient Interface
    • Patient Preferences
  • Device Development and As-Supplied Packaging
    • Device Supplier Segment Analysis
    • Pre- and Post-marketing Device Evolution

Self-administered Enabling Devices

  • Device Selection - Stability and Materials Issues
  • Prefilled Syringes
  • Autoinjectors
    • Manual Injection Autoinjectors
    • Automatic Injection Autoinjectors
    • Special Feature Autoinjectors
    • Variable Dose Autoinjectors
  • Pen Injectors
  • Emerging Devices

Self-administered Therapeutic Autoimmune Drug Assessment

Therapeutic Market Segment Analysis & Forecasts

Market Factors

  • Regulatory Factors
  • Clinical Trial Protocols & Endpoints
  • Alliances and Partnerships

Company Profiles

Back to Top
전화 문의